Navigation Links
American Society of Clinical Oncology recognizes MD Anderson leaders for their contributions to cancer research
Date:6/2/2014

Cancer research and treatment has evolved significantly in the past five decades. As the American Society of Clinical Oncology (ASCO) celebrates its 50th anniversary, the organization named former MD Anderson president John Mendelsohn, M.D., Waun Ki Hong, M.D., and Gabriel Hortobagyi, M.D. to its list of luminaries.

Mendelsohn served as president of The University of Texas MD Anderson Cancer Center from 1996 2011 and directs its Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Mendelsohn is widely regarded for his transformative role in understanding how growth factors bind to the surface of cells and regulate their functions.

Based on his clinical and laboratory research, Mendelsohn and colleagues at the University of California San Diego developed monoclonal antibody 225, which inhibits cell proliferation by blocking the signaling pathways activated by epidermal growth factor receptors. This discovery became commercially known as Erbitux and was approved by the U.S. Food and Drug Administration for treating colon and head and neck cancers.

Mendelsohn has received numerous honors, including the Raymond Bourgine Award, Joseph H. Burchenal Clinical Research Award, the David A. Karnofsky Memorial Award, Fulbright Lifetime Achievement Medal and election to the Institute of Medicine of the National Academy of Sciences. Additionally, he's currently a fellow at the James A. Baker III Institute for Public Policy at Rice University.

Hong leads MD Anderson's Cancer Medicine division and is internationally recognized as the foremost authority on treating and preventing head and neck and lung cancers. In his nearly four-decade career, his innovative research led to seminal contributions in chemoprevention, larynx preservation and personalized therapy in lung cancer.

Hong has authored more than 660 scientific publications and trained and mentored hundreds of oncology fellows. Throughout his career, he served as president of the American Association for Cancer Research and was elected to the prestigious Institute of Medicine of the National Academy of Sciences. Hong is also a current member of the NCI's National Cancer Advisory Board.

He's received numerous awards for his clinical and translational research, including the David A. Karnofsky Memorial Award, the American Cancer Society Medal of Honor, the Rosenthal Award, Joseph H. Burchenal Award, Cancer Prevention Research Award from AACR and the Ho-Am Award from the Samsung Foundation. Hong is one of the most influential oncologists in cancer medicine today.

Gabriel Hortobagyi, M.D., professor and former chair of MD Anderson's Breast Medical Oncology, is credited with leading breakthrough advances in treating breast cancer, including combination chemotherapies for inoperable tumors and multidisciplinary care for patients at all disease stages.

Hortobagyi is widely known for a landmark study he initiated in 1974 where presurgical chemotherapy was administered to patients with widespread disease. This research concluded that many large tumors could be reduced up to 50 percent and then surgically removed. He also led a 10-year study examining a three-drug regimen given before surgery and radiation that benefited patients with advanced disease. Hortobagyi led the clinical development of several drugs (anthracyclines and taxanes) in the breast cancer field and led the definitive studies that established the role of bisphosphonates in the management of bone metastases from breast cancer.

Over the course of his career, he's authored more than 1000 scientific articles, served as president of ASCO and the International Society of Breast Diseases and chaired numerous committees, including those at the Susan G. Komen Foundation and the Breast Cancer International Research Group.

For his efforts, Hortobagyi has received worldwide honors, including the Brinker International Award for Clinical Research, the Japanese Surgical Society Medal, the Sir Peter Freyer Medal in Galway, Ireland, the Jill Rose Award, the William L. McGuire Award and was named Chevalier of the Order of la Legion d'Honneur de France in 2001.


'/>"/>

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Clinical news alert from the American Academy of Orthopaedic Surgeons
2. American College of Cardiology cites new USF Simulation Center for Training Excellence
3. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
4. Young Americans Need to Cut Calorie Intake: Study
5. Hutchinson Center president elected to American Academy of Art and Sciences
6. Can weight loss help African-American breast cancer survivors?
7. Americans Support Medicare Reform, But Not on Their Dime: Poll
8. One-third of adult Americans with arthritis battle anxiety or depression
9. Equal access to care helps close survival gap for young African-American cancer patients
10. Systemic sclerosis complications more severe in African Americans than Caucasians
11. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
American Society of Clinical Oncology recognizes MD Anderson leaders for their contributions to cancer research
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of ... Evangeline Parishes. The purpose of these scholarships is to encourage applicants to pursue ... to seek employment within these two parishes. , “We have available jobs in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug ... p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products ... increased attention from all stakeholders in the development of new chemical entities. , ...
(Date:2/12/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... Awards 2016. Finalists and winners of the ISE® Awards for both Executive and ... Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016   HeartWare International, Inc . (NASDAQ: ... to discuss its financial results for the three and ... 25, 2016 at 8:00 a.m. ET.  The company plans ... call and webcast.  On the conference call and webcast, ... the fourth quarter and business outlook.   ...
(Date:2/12/2016)... -- On Thursday, Feb. 11, 2016, surgeons at the ... Austin Medical Center successfully completed the first robotic surgery ... Surgical System with Trumpf Medical,s advanced operating table, the ... M.D., colorectal surgeon at the Texas Institute for Robotic ... technology, which seamlessly combines the da Vinci Xi Surgical ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology: